EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence <i>in situ</i> hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy

May El Sherif, Claus Peter Schneider, Carola Rabenstein, Amina Hessein Hassab, Magdy Mamdouh El Bordiny, Mona Wagdy Ayad, Katharina Pachmann

Advances in Lung Cancer · 2013

DOI: 10.4236/alc.2013.21001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Lung Cancer, 2013. Verfasst von May El Sherif und 6 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Monitoring the response of CETC to therapy in lung cancer allows early detection of patients at risk of progression. Analysis of the EGFR-gene amplification in these cells may help to characterize patients who might benefit from tyrosine kinase inhibitors.

Methods

CETCs were quantified at least twice during treatment from blood of 52 patients with advanced non small cell lung cancer (NSCLC) using fluorescence labelled anti-EpCAM. EGFR-gene amplification was analysed in these cells with double probe (EGFR/CEP7) using FISH analysis.

Results

Progression of the tumor was observed in 30 of the 52 patients (58%). With respect to changes in CETCs during therapy and progression free survival 31 patients showed a decrease in CETCs, 2 developing a single brain metastasis and 12 progressive disease; 20 patients showed an increase in CETC more than twofold 16 of which developed progressive disease. The difference was highly significant (p=0.007 Fisher’s exact test) irrespective of age, sex, tumor size, pathological type and therapy. Kaplan-Meier progression free survival was significantly different between patients with decreasing and increaseing CETC (p=0.038). 5/20 patients tested were positive for EGFR amplification with 85-100% of EpCAM positive cells showing this chromosomal abnormality. One patient could be followed during therapy with increasing CETC during therapy with bevacizumab followed by relapse. He subsequently received erlotinib resulting in a decrease in CETC and is still free of progress after 516 days.

Conclusions

These results show that peripherally circulating tumor cells in patients with advanced NSCLC are influenced by systemic chemotherapy and an increase in spite of therapy is a marker of aggressiveness of the tumor cells. Determination of the EGFR amplification might help to better treat part of these patients.

Zitieren

APA

Sherif, M. E., Schneider, C. P., Rabenstein, C., Hassab, A. H., Bordiny, M. M. E., Ayad, M. W., & Pachmann, K. (2013). Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence in situ hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy. Advances in Lung Cancer. https://doi.org/10.4236/alc.2013.21001

Vancouver

Sherif ME, Schneider CP, Rabenstein C, Hassab AH, Bordiny MME, Ayad MW, et al. Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence in situ hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy. Advances in Lung Cancer. 2013. doi:10.4236/alc.2013.21001

BibTeX
@article{Sherif2013,
  author = {Sherif, May El and Schneider, Claus Peter and Rabenstein, Carola and Hassab, Amina Hessein and Bordiny, Magdy Mamdouh El and Ayad, Mona Wagdy and Pachmann, Katharina},
  title = {Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence in situ hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy},
  journal = {Advances in Lung Cancer},
  year = {2013},
  doi = {10.4236/alc.2013.21001}
}
Kostenlos starten →